St. Jude Medical receives Japanese approval
Interventional device developer St. Jude Medical said that the Japanese Ministry of Health, Labor and Welfare has given regulatory and reimbursement approval for use of its Angio-Seal STS Plus vascular closure device in that country.

It has been approved for both percutaneous peripheral and cardiac interventional catheterization procedures and enables physicians to seal femoral artery punctures made during those procedures, according to the St. Paul, Minn.-based company.

The Angio-Seal STS Plus device includes a bio-resorbable anchor, suture and collagen pad. The anchor is placed in the artery through a delivery system and secured against the artery’s interior wall. Then the collagen pad, which is positioned on the outside of the artery, is bound together with the suture to form a seal. The self-tightening suture enables the physician to finalize the closure procedure immediately, St. Jude Medical said.

All components of the Angio-Seal STS Plus device are fully absorbed within 60 to 90 days, according to the firm.